[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperglycemia-drug-induced\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperglycemia-drug-induced":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100568804","phase-4-effect-of-timing-of-dexamethasone-during-induction-on-postoperative-outcomes-100568804",false,"NCT06685991","Effect of Timing of Dexamethasone During Induction on Postoperative Outcomes","Effect of Timing of Dexamethasone Administration During Induction on Postoperative Outcomes: A Triple-Blinded Randomized Controlled Trial","TIDE","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled for elective non cardiac surgery requiring general anesthesia\n* surgery last at least 90 minutes\n* scare of more than 5 cm Able to provide informed consent Eligible for dexamethasone administration as part of routine perioperative care\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to dexamethasone or related corticosteroids\n* History of uncontrolled diabetes mellitus or significant blood glucose management issues, as dexamethasone may affect glucose levels\n* Severe cardiovascular instability or hemodynamic issues contraindicating study participation\n* Patients receiving immunosuppressive therapy or with conditions affecting the immune system, as corticosteroids may alter immune responses\n* Pregnancy or breastfeeding, due to potential risks to the fetus or infant\n* Current or recent (within 30 days) use of other glucocorticoids, which may interfere with study outcomes\n* Patients with psychiatric or cognitive conditions that impair their ability to consent or adhere to study protocols\n* Lack of informed consent","ALL","18 Years","70 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study aims to investigate how the timing of dexamethasone administration during anesthesia induction affects patient outcomes after surgery. Dexamethasone is commonly used to reduce nausea and inflammation during and after surgery. However, it is not yet known if administering dexamethasone at different times during induction (before, during, or after specific anesthetic drugs) leads to better recovery and fewer postoperative complications.\n\nParticipants will be randomly assigned to one of three groups: one group will receive dexamethasone before fentanyl, another after the muscle relaxant, and a third group will not receive dexamethasone. This approach will help us understand if the timing of dexamethasone affects patient outcomes such as nausea, pain, and recovery quality. The study is triple-blinded, meaning that the participants, care providers, and investigators will not know which group the participants are in, to ensure unbiased results.",[28,29,30,31,32,33],"Postoperative Nausea and Vomiting (PONV)","Postoperative Pain","Inflammatory Response to Wounding","Hyperglycemia Drug Induced","Hypotension on Induction","Timing of Dexamethasone Administration",[35,36,37,38,39,40,41],"Dexamethasone","Timing of Administration","Anesthesia Induction","Randomized Controlled Trial (RCT)","Triple-Blinded Study","Induction Protocol","Postoperative outcomes","NOT_YET_RECRUITING","2024-11-10",{"date":45,"type":46},"2024-11-13","ACTUAL",{"date":48,"type":22},"2024-12-01",{"date":50,"type":22},"2026-01-31",{"name":52,"class":53},"AABDI Mohammed","OTHER",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100497162","early-phase-1-a-pilot-study-of-monitoring-insulin-levels-and-treating-hyperinsulinemia-and-hyperglycemia-with-pioglitazone-in-patients-treated-with-alpelisib-for-metastatic-breast-cancer-100497162","NCT05753657","A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.","Inclusion Criteria:\n\n* Patients with ER positive HER2 negative metastatic breast cancer, harboring an activating PIK3CA mutation, scheduled to start treatment with Alpelisib and fulvestrant.\n* Ages 18 - 85\n* ECOG performance status 0, 1 or 2\n* Ability to understand and willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Alpelisib\n* Uncontrolled diabetes mellitus, defined as HbA1c above 8%\n* Diabetes mellitus controlled by insulin\n* Uncontrolled intercurrent illness including, but not limited to: active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnancy\n* Known allergy to pioglitazone","FEMALE","85 Years",{"count":63,"type":22},30,[65],"EARLY_PHASE1","The goal of this study is to test whether monitoring insulin levels and using pioglitazone to treat hyperglycemia and hyperinsulinemia in patients treated with Alpelisib for metastatic breast cancer is feasible and safe, and to assess the rates of glycemic control, dose reductions and treatment discontinuation and the progression free survival of patients treated with this regimen.",[68,69,31],"Metastatic Breast Cancer","Hyperinsulinism","RECRUITING","2023-02-22",{"date":73,"type":46},"2023-03-03",{"date":75,"type":46},"2022-12-25",{"date":77,"type":22},"2027-12-31",{"name":79,"class":53},"Rambam Health Care Campus",1]